MILLVILLE

Cancer Incidence by Sex, 1993 - 1997 Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | <u>SIR</u> | | Exp | <u>Obs</u> | SIR |
|------------------------|-----------|--------------|-------------------------|-----------------|------|------------|-----|
| Bladder, Urinary | <u>Y</u> | | Melanoma of Skin | | | | |
| Male | 1.05 | 1 | NC* | Male | 0.76 | 2 | NC* |
| Female | 0.41 | 0 | NC* | Female | 0.65 | 0 | NC* |
| Total | 1.46 | 1 | NC* | Total | 1.41 | 2 | NC* |
| Brain and Other | Central N | ervous Syste | Multiple Myel | <u>oma</u> | | | |
| Male | 0.46 | 0 | NC* | Male | 0.20 | 0 | NC* |
| Female | 0.39 | 0 | NC* | Female | 0.19 | 0 | NC* |
| Total | 0.85 | 0 | NC* | Total | 0.40 | 0 | NC* |
| Breast | | | Non-Hodgkin's Lymphoma | | | | |
| Male | 0.07 | 0 | NC* | Male | 1.02 | 1 | NC* |
| Female | 7.61 | 10 | 131 | Female | 0.84 | 0 | NC* |
| Total | 7.68 | 10 | 130 | Total | 1.86 | 1 | NC* |
| Cervix Uteri | | | Oral Cavity and Pharynx | | | | |
| | | | | Male | 0.83 | 0 | NC* |
| Female | 0.58 | 0 | NC* | Female | 0.38 | 0 | NC* |
| | | | | Total | 1.20 | 0 | NC* |
| Colon / Rectum | | | Ovary | | | | |
| Male | 2.70 | 4 | NC* | | | | |
| Female | 2.59 | 2 | NC* | Female | 0.95 | 1 | NC* |
| Total | 5.29 | 6 | 113 | | | | |
| Esophagus | | | | Pancreas | | | |
| Male | 0.42 | 0 | NC* | Male | 0.43 | 0 | NC* |
| Female | 0.13 | 0 | NC* | Female | 0.44 | 0 | NC* |
| Total | 0.55 | 0 | NC* | Total | 0.87 | 0 | NC* |
| Hodgkin's Disea | se | | Prostate | | | | |
| Male | 0.27 | 0 | NC* | Male | 6.75 | 2 | NC* |
| Female | 0.21 | 0 | NC* | | | | |
| Total | 0.47 | 0 | NC* | | | | |
| Kidney and Rena | al Pelvis | | Stomach | | | | |
| Male | 0.70 | 0 | NC* | Male | 0.47 | 0 | NC* |
| Female | 0.42 | 0 | NC* | Female | 0.28 | 0 | NC* |
| Total | 1.12 | 0 | NC* | Total | 0.75 | 0 | NC* |
| <u>Larynx</u> | | | | Testis | | | |

| Male | 0.43 | 0 | NC* | Male | 0.41 | 0 | NC* |
|-----------------------------------|------|---|-------------------|--------------------------------------|-------|----|-----|
| Female | 0.12 | 0 | NC* | | | | |
| Total | 0.55 | 0 | NC* | | | | |
| Leukemia | | | | Thyroid | | | |
| Male | 0.55 | 2 | NC* | Male | 0.18 | 0 | NC* |
| Female | 0.43 | 0 | NC* | Female | 0.49 | 1 | NC* |
| Total | 0.98 | 2 | NC* | Total | 0.68 | 1 | NC* |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 0.24 | 1 | NC* | | | | |
| Female | 0.09 | 0 | NC* | Female | 1.42 | 0 | NC* |
| Total | 0.33 | 1 | NC* | | | | |
| Lung and Bron | chus | | All Sites / Types | | | | |
| Male | 3.63 | 3 | NC* | Male | 23.24 | 16 | 69 |
| Female | 2.83 | 0 | NC* | Female | 23.08 | 17 | 74 |
| Total | 6.46 | 3 | NC* | Total | 46.32 | 33 | 71 |
| | | | | | | | |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \leq 0.001$ level, as well as at the $\mathbf{p} \leq 0.05$ and $\mathbf{p} \leq 0.01$ levels